Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$12.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 789.68% year-over-year to -$12.1 million in Q1 2026; TTM through Mar 2026 was $18.3 million, a 71.52% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, up 117.64% from the prior year.
• Change in Accured Expenses eased to -$12.1 million in Q1 2026 per CRNX's latest filing, from $11.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $12.5 million in Q2 2025 and bottomed at -$12.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $4.1 million (2022), against an average of $3.2 million.
• Across the five-year window, Change in Accured Expenses jumped 866.13% in 2025 and slumped 789.68% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $4.1 million in 2022, then tumbled by 53.47% to $1.9 million in 2023, then jumped by 221.89% to $6.1 million in 2024, then soared by 82.73% to $11.2 million in 2025, then tumbled by 207.95% to -$12.1 million in 2026.
• Per Business Quant, the three latest CRNX Change in Accured Expenses figures stand at -$12.1 million (Q1 2026), $11.2 million (Q4 2025), and $6.6 million (Q3 2025).